Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psoriasis breakthrough: lower drug doses may work just as well

NCT ID NCT04340076

Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether psoriasis patients who are stable on biologic drugs (IL17 or IL23 inhibitors) can safely reduce their dose without their skin condition getting worse. Researchers enrolled 244 adults with plaque psoriasis who had been on a normal dose for at least 6 months. Participants were randomly assigned to either continue their usual dose or gradually lower it. The goal was to see if dose reduction is as effective as standard care in preventing persistent flares.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
IL17 and IL23 inhibitors (Secukinumab, Ixekizumab, Brodalumab, Guselkumab)
What this could lead to
If successful, this could show that many psoriasis patients can safely lower their biologic dose without flare-ups, reducing side effects and costs.
What could go wrong
This is a completed Phase 4 study with 244 participants, so results are available but may not apply to all patients. Dose reduction might not work for everyone and could lead to disease flares.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

244 people

The number who actually took part.

Started

Aug 2020

Finished

Jan 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Plaque psoriasis (primarily) * Treatment for at least 6 months with IL23 or IL17 inhibitor in a normal dose (dose advised by the label) * PASI≤ 5 at inclusion and in previous 6 months (if no PASI scores are available, it should be clear from the patient record that psoriasis was clear/almost clear in previous 6 months). * DLQI ≤ 5 at inclusion Exclusion Criteria: * Another indication than plaque psoriasis as the main indication for biologic use (e.g. patient receives biologic for rheumatoid arthritis as the main indication). * Concomitant use of systemic immunosuppressants other than methotrexate or acitretin (e.g. prednisone, cyclosporine etc). * Severe comorbidities with short life-expectancy (e.g. metastasized tumor). * Presumed inability to follow the study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis Skin Diseases, Papulosquamous skin disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis Psoriasis vulgaris

Contacts and locations

Locations

  • AZ Maria Middelares

    Ghent, Belgium

  • AZ St Lucas

    Ghent, Belgium

  • Amphia Hospital

    Breda, Netherlands

  • Bravis hospital

    Bergen op Zoom, Netherlands

  • CHU Liege

    Liège, Belgium

  • Catharina hospital

    Eindhoven, Netherlands

  • Dermatologie Maldegem

    Maldegem, Belgium

  • Erasmus MC

    Rotterdam, Netherlands

  • Ghent University Hospital

    Ghent, 9000, Belgium

  • Maastricht UMC

    Maastricht, Netherlands

  • Máxima Medisch Centrum

    Veldhoven, Netherlands

  • Radboudumc

    Nijmegen, 6500HB, Netherlands

  • Slingeland hospital

    Doetinchem, Netherlands

  • UCL Saint Luc

    Leuven, Belgium

  • ULB Erasme

    Brussels, Belgium

  • UMC Groningen

    Groningen, Netherlands

  • UMC Utrecht

    Utrecht, Netherlands

  • UZ Leuven

    Leuven, Belgium

  • Ziekenhuisgroep Twente

    Almelo, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.